TROBICIN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TROBICIN (TROBICIN).
Spectinomycin inhibits protein synthesis in susceptible bacteria by binding to the 30S ribosomal subunit, thereby blocking the initiation of peptide chain elongation.
| Metabolism | Primarily excreted unchanged in urine; minimal hepatic metabolism. |
| Excretion | Renal: >90% unchanged via glomerular filtration; biliary/fecal: <5%. |
| Half-life | 1.0-1.7 hours in normal renal function; prolonged to 10-24 hours in anuria; clinical context: dosing interval adjustment required in renal impairment. |
| Protein binding | Weakly bound (10-15%) to albumin. |
| Volume of Distribution | 0.20-0.25 L/kg; indicates distribution primarily into extracellular fluid. |
| Bioavailability | IM: 100% (complete absorption). |
| Onset of Action | IM: 1-2 hours (peak serum levels); IV: immediate (end of infusion). |
| Duration of Action | IM/IV: 8-12 hours (bactericidal levels); clinical note: single-dose therapy for uncomplicated gonorrhea. |
| Molecular Weight | 332.31 |
2 g intramuscularly as a single dose; for severe infections, 4 g intramuscularly as a single dose or 2 g intramuscularly every 12 hours for 2 days.
| Dosage form | INJECTABLE |
| Renal impairment | CrCl 10-50 mL/min: 2 g every 24-48 hours; CrCl <10 mL/min: 2 g every 48-72 hours. |
| Liver impairment | No specific adjustments recommended; use with caution in severe hepatic impairment. |
| Pediatric use | Children ≥2 years: 40 mg/kg intramuscularly as a single dose; maximum 2 g. For severe infections: 40 mg/kg intramuscularly every 12 hours for 2 days. |
| Geriatric use | Dose as for adults with normal renal function; monitor renal function and adjust if decreased CrCl. |
| 1st trimester | Avoid use in first trimester unless clearly needed; animal studies have shown teratogenic effects at high doses, but human data are limited. |
| 2nd trimester | Use only if clearly indicated and no safer alternative; limited human data suggest low risk but caution advised. |
| 3rd trimester | May be used if benefit outweighs risk; no known fetal harm in later pregnancy. |
Clinical note
Comprehensive clinical and safety monograph for TROBICIN (TROBICIN).
| Placental transfer | Crosses placenta; cord blood concentrations approximately 20-40% of maternal serum levels. |
| Breastfeeding | Excreted into breast milk in low concentrations; likely compatible with breastfeeding, but monitor infant for diarrhea or rash. |
| Lactation Rating |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to spectinomycinHypersensitivity to any aminoglycoside-like antibiotics
| Precautions | Not effective against syphilis; may mask or delay syphilis symptoms; use with caution in patients with renal impairment; allergic reactions including anaphylaxis reported; contains benzyl alcohol which may cause toxicity in neonates. |
| Food/Dietary | No clinically significant food interactions have been reported for Trobicin. It is administered intramuscularly, so oral intake does not affect absorption or efficacy. However, alcohol consumption should be avoided during treatment for gonorrhea as it may increase the risk of adverse effects like dizziness or nausea, though not a direct food-drug interaction. |
Loading safety data…
| L2 (Probably Compatible) |
| Teratogenic Risk | No evidence of teratogenicity in animal studies; human data limited. Risk cannot be excluded; use only if clearly needed during all trimesters. |
| Fetal Monitoring | Monitor for hypersensitivity reactions, renal function, and hearing (if ototoxicity suspected). Fetal monitoring for growth and well-being if used in pregnancy. |
| Fertility Effects | No known adverse effects on fertility in animal studies; human data insufficient. |
| Clinical Pearls | Trobicin (spectinomycin) is a parenteral aminocyclitol antibiotic used primarily for the treatment of uncomplicated gonorrhea caused by penicillinase-producing Neisseria gonorrhoeae (PPNG). It is not effective against syphilis and may mask or delay symptoms of incubating syphilis. Administer as a single intramuscular injection (2 g for men, 4 g for women, divided into two injection sites) to overcome resistance and achieve therapeutic levels. Trobicin does not treat chlamydial co-infections; concurrent azithromycin or doxycycline should be considered. Monitor for injection site pain and rare anaphylaxis. Not recommended for pharyngeal gonorrhea due to poor efficacy. |
| Patient Advice | Trobicin is given as a shot, usually a single dose, to treat gonorrhea. · You must take any additional antibiotics prescribed for chlamydia or other infections. · Notify your healthcare provider immediately if you experience difficulty breathing, hives, or swelling after the injection. · A follow-up test is recommended in 3 to 7 days to confirm the infection is cured. · Abstain from sexual activity until you and your partner(s) have completed treatment and symptoms have resolved to prevent reinfection. · Report any unusual discharge, pelvic pain, or testicular pain that persists after treatment. · This medication does not prevent future sexually transmitted infections; use condoms consistently. |